ArticleCase reports in oncological medicine2016

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.

Wilfred Delacruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.